Pharma — India Patent Cases
967 decisions indexed
Page 32 of 33 · 967 total
N/A v.N/A
The Lok Sabha debated the Patents (Amendment) Bill, 2005, which sought to introduce product patents. Opposition members strongly argued that this change would lead to exorbitant drug prices, making essential medicines inaccessible to the common man, thereby violating the fundamental right to health under Article 21. Despite these concerns, the Minister of Commerce and Industry successfully moved the motion, and the Bill was ultimately passed by the House.
The Government of India v.Concerned Citizens/Pharmaceutical Industry Stakeholders
The debate centered on the introduction of a Bill to further amend the Patents Act, 1970. Opponents argued that the amendment would compromise India's strong generic drug industry and restrict public access to affordable life-saving medicines. The Speaker ultimately allowed the motion for introducing the Bill to be adopted.
Novartis Ag And Anr. v.Mehar Pharma And Anr.
Novartis sought an interim injunction restraining Mehar Pharma from manufacturing, selling, or exporting its anti-cancer drug 'VEENAT', which was alleged to infringe Novartis's Exclusive Marketing Rights (EMR) for 'B-crystalline form of imatinib Mesyiate salt'. The court ultimately denied the temporary injunction, citing concerns about disrupting the supply of this life-saving drug in India.
Intas Laboratories Pvt. Ltd. And Anr. v.Novaritis A.G., Schwarzwaldallee,
The dispute concerned the validity of an Exclusive Marketing Right (EMR) granted to Novaritis for the anti-cancer drug, Beta-Crystalline form of Imatinib Mesylate. Intas Laboratories challenged this EMR, arguing it created a monopoly and harmed public interest due to high pricing. The Madras High Court confirmed the interim injunction but mandated that the plaintiffs supply the drug freely to eligible patients.
Novartis Ag v.Adarsh Pharma And Anr.
The plaintiff, Novartis Ag, sought to confirm an ex parte injunction granted under Exclusive Marketing Rights (EMR) for its product, Beta Crystalline form of Imatinib Mesylate. The defendant challenged this injunction, arguing that no patent was ever filed in India and the EMR was vague. The court ultimately confirmed the injunction, finding prima facie materials favored the plaintiffs.
Sun Pharmaceutical Industries Limited v.Wyeth Holdings Corporation And Anr.
The Bombay High Court dismissed the appeal filed by Sun Pharmaceutical Industries Limited against an interim order favoring Wyeth Holdings Corporation. The core dispute involved alleged infringement and passing off, where Wyeth held the registered trademark 'Pacitane' for anti-spasmodic preparations, and Sun used 'Parkitane'. The court found that due to the identical field of activity, common composition (Trihexylphenidyl), and high likelihood of consumer confusion, the appellants' use was fraudulent. Consequently, the court upheld the protective order granted to Wyeth.
Raptakos Brett & Co. Ltd. v.Cadila Laboratories Ltd.
Raptakos Brett & Co. Ltd. opposed the trademark application for NEOPLATIN by Cadila Laboratories Ltd., arguing that it was phonetically, visually, and structurally similar to their registered mark NEOPEPTINE. The Tribunal found an apparent conflict between the marks based on overall impression and sustained the opposition.
Aviat Chemicals Pvt. Ltd. v.Magna Laboratories (Gujarat) Pvt. Ltd.
The plaintiffs filed a civil suit seeking permanent injunction against the defendant for infringing the registered trade mark MVI. The defendant challenged the validity of the registration and alleged that the plaintiff had been using the mark earlier, thus claiming prior user rights. The court ultimately found prima facie evidence of inordinate delay on the part of the plaintiffs.
Torrent Pharmaceuticals Ltd. v.The Wellcome Foundation Ltd.
The Gujarat High Court upheld the refusal of trademark registration for 'TROVIREX' filed by Torrent Pharmaceuticals Ltd. The court found that TROVIREX was deceptively similar to Wellcome Foundation Ltd.'s registered trademarks, ZOVIREX and ZOVIREX, particularly because both marks were used in relation to pharmaceutical products (similar goods). Citing established legal principles, the court concluded that allowing the registration would likely deceive consumers and cause confusion regarding the origin of the medicinal preparations.
Cadila Healthcare Limited v.Cadila Pharmaceuticals Limited
The dispute arose from a suit filed by Cadila Healthcare Limited against Cadila Pharmaceuticals Limited regarding the use of trade marks Falcigo and Falcitab for drugs treating cerebral malaria. The appellant claimed that the respondent's mark would cause passing off due to confusing similarity, especially since both were medicines of last resort.
Richardson Vicks Inc. v.Raj Remedies
The plaintiffs (Richardson Vicks Inc.) sought an injunction against the defendants (Raj Remedies) alleging infringement of their registered trade mark 'VICKS' and copyright in the artistic label, by using the deceptively similar marks/get-up like 'VIKAS'. The Gujarat High Court upheld the City Civil Court's interim order, finding that a prima facie case for deceptive similarity existed.
Cadila Healthcare Ltd. v.Union Of India (Uoi) And Ors.
Cadila Healthcare Ltd. challenged an order that rejected its plea to treat opposition proceedings against its 'CONAZOLE' trademark application as abandoned. The respondent (Uoi) argued that the opposing party had filed evidence, and Cadila failed to file its counter-evidence within the stipulated time. The court ultimately upheld the Registrar's decision to grant an extension of time, finding no infirmity in the order.
Wockhardt Limited v.Aristo Pharmaceuticals Limited
The Madras High Court ruled in favor of Wockhardt Limited, upholding the original ex parte injunction against Aristo Pharmaceuticals. The court found that despite the respondent's arguments regarding industry practice and generic terms, there was a likelihood of deception or confusion among unwary consumers due to the phonetic and visual similarity between the marks 'SPASMO-PROXYVON' and 'SPASMO-FLEXON'. This decision reinforces the principle that overall similarity is the key factor when assessing trademark infringement in the pharmaceutical sector.
Cadila Healthcare Ltd. v.Union Of India And Ors.
Cadila Healthcare Ltd. challenged an order that rejected its petition seeking to treat a trademark opposition (filed by M/s. Wockhordt Ltd.) as abandoned. The petitioner argued that the delay in filing evidence was prejudicial. The court examined the Registrar's power to grant extensions under Section 101 of the Act and held that such an extension is permissible, thus saving the opposition proceedings.
Winthrop Products Inc. v.Eupharma Laboratories Ltd.
The plaintiffs sought an injunction against defendants for infringing their registered trade mark, PANADOL, and passing off. The court found that the plaintiffs were the rightful proprietors of the trade mark and that the defendants lacked any vested right to use the name. Consequently, the defendants were prevented from using or passing off the trade mark.
Burroughs Wellcome (India) Ltd. v.Uni-Sole Pvt. Ltd. & Another
The plaintiffs, owners of the trademark "Septran" and copyright in its carton, sued the defendants for infringement and passing off. The plaintiffs alleged that the defendants were using a deceptively similar mark ("Simptran") and an identical or substantially similar carton design for their product Simptran Tablets. The court passed an interim order restraining the defendant from continuing these infringing activities pending final disposal of the suit.
Burroughs Wellcome (India) Ltd. v.Uni-Sole Pvt. Ltd. And Another
The plaintiffs, owners of the trademark 'Septran' and copyrights in its carton design, sued the defendants for infringing these rights. The plaintiffs alleged that the defendants were deceptively imitating their product ('Simptran Tablets') using a similar carton and mark since 1993.
M/S. Jagsonpal Pharmaceutical Ltd. v.M/S. Senor Laboratories
The plaintiff filed a suit for injunction against the defendant on the ground of passing off, alleging that the defendant was using the identical pharmaceutical trade mark SEFLOX. The dispute centered on who had invented and used the trade mark first, with both parties presenting evidence of their respective usage dates.
American Home Products Corporation v.Lupin Laboratories Ltd.
The plaintiff filed an infringement action alleging that the defendant was using the deceptively similar trade mark "TOROLAC" for analgesic tablets, infringing upon the plaintiff's registered trade mark "ROLAC". The court found that the marks were deceptively similar and satisfied that the plaintiffs had made out a prima facie case of infringement.
Astra-Idl Limited v.Ttk Pharma Limited
Astra-Idl Limited filed a suit against Ttk Pharma Limited alleging infringement and passing off of its registered trade mark 'Betaloc' (used for pharmaceutical preparations) by the defendant using the similar trade mark 'Betalong'. The court found that the plaintiff had made out a strong prima facie case for interlocutory relief, despite arguments regarding delay.
M/S. Antex India Pvt. Ltd. Bangalore v.M/S. Wander Ltd., Bombay And Etc.
The dispute arose from an agreement where Antex was authorized by Wander to manufacture and affix the trademark 'Cal-De-Ce'. When Wander arranged for a third party (Alfred Berg & Company) to produce the product, Antex sought permanent injunctions. The Madras High Court addressed writ appeals concerning the cancellation of Antex's manufacturing license.
N.V. Philips Gloeilempenfabrieken Bindhhoven, Holland v.Commissioner Of Income-Tax (No. 1)
This case involved a dispute over whether payments received by N.V. Philips from an Indian company for providing technical knowledge regarding Vitamin D manufacturing constituted a technical assistance fee or royalty. The core issue revolved around the nature of the agreement, which granted exclusive use of confidential processes and information to the Indian company under strict secrecy terms. The court ultimately held that because the process was treated as an exclusive secret property by Philips, the payment bore the character of royalty.
American Home Products Corporation v.Mac Laboratories Private Limited And Anr.
American Home Products Corporation (Appellant) sought to protect its registered trade mark 'Dristan'. Mac Laboratories Private Limited (Respondent) challenged the registration, leading to appeals regarding the validity and rectification of the trademark.
Sandoz Limited And Anr. v.Pharmaceutical And Chemical ...
The plaintiffs, holding the registered trademark 'Syntocinon', filed a suit against defendants marketing 'Synthocilin' due to alleged deceptive similarity. The trial court declined an interim injunction, leading to this appeal. The High Court considered the prior finding of deceptive similarity but opted for settlement rather than granting immediate restraint.
Amrutanjan Limited v.Amarchand Sobachand
Amrutanjan Limited sued Amarchand Sobachand for infringing its registered trade mark 'AMRUTANJAN' used on pain balm. The plaintiffs alleged that the defendant was using a deceptively similar name ('Amar's Pain Balm') and an imitation carton design, leading to consumer confusion. The court found infringement but dismissed claims for damages as passing off was not proven.
Indo-Pharma Pharmaceutical Works v.Pharmaceutical Company Of India
The plaintiff, proprietor of 'BUTACORTINDON', filed an infringement suit against the defendant, proprietor of 'BUTACORT'. The plaintiffs alleged that the defendant's use of BUTACORT constituted infringement. However, the defendants successfully argued that they were prior continuous users and thus entitled to protection under Section 33 of the Trade and Merchandise Marks Act, 1958.
Mount Mettur Pharmaceuticals Ltd. v.Ortha Pharmaceuticals Corporation
Mount Mettur Pharmaceuticals Ltd. applied for registration of its trade mark 'Utogynol', which was opposed by Ortho Pharmaceuticals Corporation due to perceived similarity with their registered trade mark 'Ortho-Gynol'. The court examined the look and sound of both names, finding that despite sharing the common element 'Gynol', the initial syllables ('Uto' vs. 'Ortho') were strikingly dissimilar.
F. Hoffmann-La Roche & Co. Ltd. v.Geoffrey Manners & Co. Pvt. Ltd.
The petitioner sought rectification of the trade mark register to remove the respondent's mark 'DROPOVIT', alleging it was deceptively similar to their registered mark 'PROTOVIT'. The case also involved determining if 'DROPOVIT' was a descriptive or invented word. The Supreme Court dismissed the appeal, finding no reasonable probability of confusion and confirming that 'DROPOVIT' was an invented word.
Farbewerke Hoechst v.Unichem Laboratories And Ors.
Farbewerke Hoechst sued Unichem Laboratories for infringing Patent No. 58716, which covered the manufacture of sulphonyl-ureas like Tolbutamide (marketed as Rastinon). The defendants claimed non-infringement and challenged the validity of the patent. The court found that the plaintiffs' patent was valid and granted an injunction against the defendants.
Mac Laboratories Private Ltd. v.American Home Products Corporation And Registrar of Trade Marks
In this 1968 Calcutta High Court appeal, Mac Laboratories Private Ltd. successfully challenged the registration of the trademark 'Dristan' belonging to American Home Products Corporation. The court ruled that the original registration was contrary to law because there was no bona fide intention by the proprietor to use the mark in India. Furthermore, the appellant argued grounds including lack of distinctiveness and deceptive similarity to other marks, ultimately leading the court to allow the appeal and rectify the register.
Dealing with a patent challenge?
Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.